Moreover, RAC1-DOCK1 binding blockade genetically or pharmacologically, by using TBOPP, has demonstrated to cancel RAC1P29S nucleotide exchange and to lessen melanoma and breast cancer matrix invasion [74]. This evidence concerns the gene RAC1 and breast carcinoma.